'Nyha class' presentation slideshows

Improving Outcomes in Heart Failure: New Insights From Vascular Biology

Improving Outcomes in Heart Failure: New Insights From Vascular Biology. Heart Failure: A Public Health Concern. 20% Lifetime risk for HF after age 40. Framingham Heart Study. Men. Women. 25. 25. 20. 20. 15. 15. Cumulative risk (%). 10. 10. 5. 5. 0. 0. 0. 40. 50. 50. 60.

635 views • 53 slides

548 views • 41 slides

Time irreversibility analysis: a tool to detect non linear

Time irreversibility analysis: a tool to detect non linear dynamics in short-term heart period variability. Alberto Porta. Department of Biomedical Sciences for Health Galeazzi Orthopedic Institute University of Milan Milan, Italy. Introduction.

507 views • 40 slides

Anaesthetic management of obstetric patient for heart disease.

Anaesthetic management of obstetric patient for heart disease. SPEAKER DR. PRAGATI NANDA. MODERATOR DR. SANJEEV ANEJA. www.anaesthesia.co.in anaesthesia.co.in@gmail.com. Case presentation. 29yr F resident of massigarh village. c/c amenorrhea x 8 months.

664 views • 36 slides

Gian Piero Perna & D Gabrielli, F Guazzarotti, A Moraca, C Corinaldesi

628 views • 35 slides

Anaesthetic management of obstetric patient with MS.

733 views • 35 slides

Working Group of Heart Failure and Cardiac Function

402 views • 25 slides

Myocardial Recovery: Stem Cell Therapy - are we getting there?

Myocardial Recovery: Stem Cell Therapy - are we getting there?. Professor Anthony Mathur Queen Mary University of London Barts and the London NHS Trust. Yes. efficacy. preclinical promise?. Source and Administration in AMI Trials.

359 views • 24 slides

Disclosure

Prognostic Value of Programmed Electrical Stimulation Among Implantable Cardioverter -Defibrillator Recipients Real-World Data from the Israeli National ICD Registry.

374 views • 23 slides

R Grimm : Speaker - St. Jude, Medtronic, GE Research Grant - GE

Presenter Disclosure Information John F. Beshai, MD RethinQ Trial Results Disclosures Information: The following relationships exist related to this presentation: Consultant - St. Jude Medical, Atricure Research Grant - St. Jude Medical. R Grimm : Speaker - St. Jude, Medtronic, GE

373 views • 22 slides

Valve Regurgitation

Valve Regurgitation. Echocardiographic Calculations Rami Khouzam, MD. Definitions/Equations:. Continuity equation: Flow (SV) = LVEDV - LVESV = A x TVI (SV:Stroke Volume, A: Area, TVI:Time Velocity Integral) Flow 1(SV) = Flow 2 (SV) A1 x TVI 1 = A2 x TVI2.

627 views • 20 slides

Valve Regurgitation

Valve Regurgitation. Echocardiographic Calculations Rami Khouzam, MD. Definitions/Equations:. Continuity equation: Flow (SV) = LVEDV - LVESV = A x TVI (SV:Stroke Volume, A: Area, TVI:Time Velocity Integral) Flow 1(SV) = Flow 2 (SV) A1 x TVI 1 = A2 x TVI2.

372 views • 20 slides

Results of the Pr edictors o f Re sp ons e to C R T ( PROSPECT) Trial

Results of the Pr edictors o f Re sp ons e to C R T ( PROSPECT) Trial Chung ES, Leon AR, Tavazzi L, Sun J-P, Nihoyannopoulos P, Merlino J, Abraham WT, Ghio S, Leclercq C, Bax JJ, Yu C-M, Gorcsan J 3rd, St John Sutton M, De Sutter J, Murillo J,. Circulation. 2008;117:2608-2616.

384 views • 14 slides

British Heart Valve Society Carcinoid Heart Disease

British Heart Valve Society Carcinoid Heart Disease. Dr C Hayward MB BChir MRCP , Dr S Bhattacharyya MD MRCP, Dr J Davar MD PhD Royal Free Hospital, London, UK. Case Presentation. Clinical History 60 year old female.

547 views • 12 slides

Introduction

`. Prevalence of Low T3 syndrome and its association with severity in patients of Chronic heart failure : A hospital based study Sangeet Saurav , Abhinaba Debnath ,Anupam Singh, Rajendra Jha Department of Medicine , RIMS,Ranchi. Introduction.

196 views • 12 slides

Management of Chronic Heart Failure SIGN 95

Management of Chronic Heart Failure SIGN 95. Chronic Heart Failure (CHF). Diagnosis Treatment drugs after ACEI/BB devices models of care. BNP (or NT pro-BNP) and/or ECG. Diagnostic algorithm for patients with suspected CHF. Symptoms or signs suggestive of CHF. Clinical examination

370 views • 9 slides

Randomized Angioplasty Beta Blocker Intracoronary Trial II (RABBIT II)

RABBIT II Trial. Randomized Angioplasty Beta Blocker Intracoronary Trial II (RABBIT II). Presented at The American Heart Association Scientific Session 2006 Presented by Dr. Barry F. Uretsky. RABBIT II Trial: Background.

310 views • 8 slides

Chronicle Offers Management to Patients with Advanced Signs and Symptoms of Heart Failure

COMPASS-HF. Chronicle Offers Management to Patients with Advanced Signs and Symptoms of Heart Failure . Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Robert C. Bourge. COMPASS-HF.

197 views • 6 slides

Assessment of a New Mesh Cardiac Support Device (CSD) in Patients with Heart Failure

ACORN Trial. Assessment of a New Mesh Cardiac Support Device (CSD) in Patients with Heart Failure. Presented at The American Heart Association Scientific Sessions 2004 Presented by Dr. D.L. Mann. ACORN Trial. 300 Patients with Heart Failure 81.3% NYHA Class III, 3.7% Class IV

234 views • 6 slides

Severe heart failure P= 0.16

Primary composite end point in patients with severe HF or less severe HF ( time-to-first event). Severe heart failure P= 0.16. Incidence of primary composite endpoint (%). Less severe heart failure P< 0.001. Severe HF (NYHA class IV and/or LVEF 20%)

93 views • 1 slides